Dishman Carbogen Amcis has informed that the Company's wholly owned subsidiary namely CARBOGEN AMCIS SAS, France, announces the release of a new batch for clinical trials of AGuIX Drug Product for NH TherAguix, a clinical stage company developing innovative nano medicine for the treatment of cancer. In this regard, it enclosed Press Release.
The above information is a part of company’s filings submitted to BSE.